Pharmacological management of depression in patients with multiple sclerosis

References

• Orton S-M, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006;5(11):932–936.
   PubMed Web of Science ®Google Scholar
• Kaufman DM, Geyer HL, Milstein MJ. Kaufman’s Clinical Neurology for Psychiatrists E-Book. New york, NY: Elsevier Health Sciences; 2016.
   Google Scholar
• Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Annals of Neurology. 2000;47(6):707–717.
   PubMed Web of Science ®Google Scholar
• Bakshi R, Czarnecki D, Shaikh ZA, et al. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport. 2000;11(6):1153–1158.
   PubMed Web of Science ®Google Scholar
• Zorzon M, Zivadinov R, Nasuelli D, et al. Depressive symptoms and MRI changes in multiple sclerosis. Eur J Neurol. 2002;9(5):491–496.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Annals of Neurology. 2005;58(6):840–846.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis The 2013 revisions. Neurology. 2014;83(3):278–286.
   PubMed Web of Science ®Google Scholar
• Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol. 2001;14(3):271–278.
   PubMed Web of Science ®Google Scholar
• Hayes CE, Acheson ED. A unifying multiple sclerosis etiology linking virus infection, sunlight, and vitamin D, through viral interleukin-10. Med Hypotheses. 2008;71(1):85–90.
   PubMed Web of Science ®Google Scholar
• Julian LJ, Vella L, Frankel D, et al. ApoE alleles, depression and positive affect in multiple sclerosis. Multiple Sclerosis Journal. 2009;15(3):311–315.
   PubMedGoogle Scholar
• Hohol M, Orav E, Weiner H. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995;45(2):251–255.
   PubMed Web of Science ®Google Scholar
• Chwastiak L, Ehde DM, Gibbons LE, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. American Journal of Psychiatry. 2002;159(11):1862–1868.
   PubMed Web of Science ®Google Scholar
• Nijeholt G, Van Walderveen M, Castelijns J, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI Parameters, Clinical Subtypes and Symptoms. Brain: a Journal of Neurology. 1998;121(4):687–697.
   Google Scholar
• McNulty K, Livneh H, Wilson LM. Perceived uncertainty, spiritual well-being, and psychosocial adaptation in individuals with multiple sclerosis. Rehabil Psychol. 2004;49(2):91.
   Web of Science ®Google Scholar
• Bakshi R, Shaikh Z, Miletich R, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Multiple Sclerosis Journal. 2000;6(3):181–185.
   PubMed Web of Science ®Google Scholar
• Nathoo N, Mackie A. Treating depression in multiple sclerosis with antidepressants: a brief review of clinical trials and exploration of clinical symptoms to guide treatment decisions. Multiple Sclerosis and Related Disorders. 2017;18:177–180.
   PubMed Web of Science ®Google Scholar
• Patten SB, Marrie RA, Carta MG. Depression in multiple sclerosis. Int Rev Psychiatry. 2017;29(5):463–472.
   PubMed Web of Science ®Google Scholar
• Amato M, Ponziani G, Rossi F, et al. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Multiple Sclerosis Journal. 2001;7(5):340–344.
   PubMed Web of Science ®Google Scholar
• Siegert R, Abernethy D. Depression in multiple sclerosis: a review. Journal of Neurology, Neurosurgery & Psychiatry. 2005;76(4):469–475.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis the 2013 revisions. Neurology. 2014;83(3):278–286.
   PubMed Web of Science ®Google Scholar
• De Pasquale C, Pistorio ML, Veroux M, et al. cognitive functioning and subjective quality of life in relapsing-remitting multiple sclerosis patients before and after percutaneous transluminal angioplasty: a preliminary report. Neuropsychiatr Dis Treat. 2014;10:1039.
   PubMed Web of Science ®Google Scholar
• Levinson DF. The genetics of depression: a review. Biol Psychiatry. 2006;60(2):84–92.
   PubMed Web of Science ®Google Scholar
• Joffe RT, Lippert GP, Gray TA, et al. Personal and family history of affective illness in patients with multiple sclerosis. Journal of Affective Disorders. 1987;12(1):63–65.
   PubMed Web of Science ®Google Scholar
• Stenager EN, Stenager E, Koch-Henriksen N, et al. Suicide and multiple sclerosis: an epidemiological investigation. Journal of Neurology, Neurosurgery & Psychiatry. 1992;55(7):542–545.
   PubMed Web of Science ®Google Scholar
• Heesen C, Böhm J, Reich C, et al. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Multiple Sclerosis Journal. 2008;14(7):988–991.
   PubMedGoogle Scholar
• Diaz-Olavarrieta C, Cummings JL, Velazquez J, et al. Neuropsychiatric manifestations of multiple sclerosis. J Neuropsychiatry Clin Neurosci. 1999;11(1):51–57.
   PubMed Web of Science ®Google Scholar
• Cetin K, Johnson K, Ehde D, et al. Antidepressant use in multiple sclerosis: epidemiologic study of a large community sample. Multiple Sclerosis Journal. 2007;13(8):1046–1053.
   PubMedGoogle Scholar
• Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry. 1990;147(11):1493.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Vortioxetine: a review in cognitive dysfunction in depression. Drugs. 2016;76(17):1675–1682.
   PubMed Web of Science ®Google Scholar
• Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008;30(1):40–48.
   PubMed Web of Science ®Google Scholar
• Paparrigopoulos T, Ferentinos P, Kouzoupis A, et al. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. International Review of Psychiatry. 2010;22(1):14–21.
   PubMed Web of Science ®Google Scholar
• Solaro C, Bergamaschi R, Rezzani C, et al. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study. Clin Neuropharmacol. 2013;36(4):114–116.
   PubMed Web of Science ®Google Scholar
• Fornaro M. Beyond monoamines towards the development of novel antidepressants. J Psychopathology. 2012;18:226–233.
   Google Scholar
• Patel K, Allen S, Haque MN, et al. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Advances Psychopharmacology. 2016;6(2):99–144.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Martino M, Mattei C, et al. Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2014;24(8):1269–1278.
   PubMed Web of Science ®Google Scholar
• Schiffer RB, Wineman NM, Weitkamp LR. Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry. 1986;143(1):94–95.
   PubMed Web of Science ®Google Scholar
• Fiest K, Walker J, Bernstein C, et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Multiple Sclerosis and Related Disorders. 2016;5:12–26.
   PubMed Web of Science ®Google Scholar
• Wiend H, Hohlfeld R. Therapeutic approaches in multiple sclerosis. BioDrugs. 2002;16(3):183–200.
   PubMed Web of Science ®Google Scholar
• Rasmussen KG, Keegan BM. Electroconvulsive therapy in patients with multiple sclerosis. J ECT. 2007;23(3):179–180.
   PubMed Web of Science ®Google Scholar
• Rietberg MB, Brooks D, Uitdehaag BM, et al. Exercise therapy for multiple sclerosis. Cochrane Lib. 2004;12:12–14.
   Google Scholar
• Minden SL. Psychotherapy for people with multiple sclerosis. J Neuropsychiatry Clin Neurosci. 1992;17:224–252.
   PubMed Web of Science ®Google Scholar
• Carta M, Moro M, Lorefice L, et al. Multiple sclerosis and bipolar disorders: the burden of comorbidity and its consequences on quality of life. Journal of Affective Disorders. 2014;167:192–197.
   PubMed Web of Science ®Google Scholar
• Hutchinson M, Stack J, Buckley P. Bipolar affective disorder prior to the onset of multiple sclerosis. Acta Neurol Scand. 1993;88(6):388–393.
   PubMed Web of Science ®Google Scholar
• Chwastiak LA, Ehde DM. Psychiatric issues in multiple sclerosis. Psychiatr Clin. 2007;30(4):803–817.
   Google Scholar
• Falk WE, Mahnke MW, Poskanzer DC. Lithium prophylaxis of corticotropin-induced psychosis. JAMA. 1979;241(10):1011–1012.
   PubMed Web of Science ®Google Scholar
• Cosentino M, Zaffaroni M, Marino F, et al. Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis. J Neuroimmunol. 2002;133(1):233–240.
   PubMed Web of Science ®Google Scholar
• Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuro-Psychopharmacology Biol Psychiatry. 1998;22(1):1–33.
   PubMed Web of Science ®Google Scholar
• Feinstein A. The neuropsychiatry of multiple sclerosis. Can J Psychiatry. 2004;49(3):157–163.
   PubMed Web of Science ®Google Scholar
• Rosenberg GA, Appenzeller O. Amantadine, fatigue, and multiple sclerosis. Arch Neurol. 1988;45(10):1104–1106.
   PubMedGoogle Scholar
• Brusaferri F, Candelise L. Steriods for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol. 2000;247(6):435–442.
   PubMed Web of Science ®Google Scholar
• Rice G, Incorvaia B, Munari LM, et al. Interferon in relapsing‐remitting multiple sclerosis. The Cochrane Library. 2001;2:15–16.
   Google Scholar
• Marrie RA, Fisk JD, Tremlett H, et al. Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology. 2015;85(22):1972–1979.
   PubMed Web of Science ®Google Scholar
• Tylee A, Gandhi P. The importance of somatic symptoms in depression in primary care. Prim Care Companion J Clin Psychiatry. 2005;7(4):167.
   PubMedGoogle Scholar
• Marck CH, De Livera AM, Weiland TJ, et al. Pain in people with multiple sclerosis: associations with modifiable lifestyle factors, fatigue, depression, anxiety, and mental health quality of life. Front Neurol. 2017;8:461.
   PubMed Web of Science ®Google Scholar
• Patel R, Dickenson AH. Mechanisms of the gabapentinoids and α2δ‐1 calcium channel subunit in neuropathic pain. Pharmacology Research & Perspectives. 2016;4:2.
   Web of Science ®Google Scholar
• Rodríguez-Muñoz M, Sánchez-Blázquez P, Vicente-Sánchez A, et al. The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control. Neuropsychopharmacology. 2012;37(2):338.
   PubMed Web of Science ®Google Scholar
• Petrenko AB, Yamakura T, Baba H, et al. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analgesia. 2003;97(4):1108–1116.
   PubMed Web of Science ®Google Scholar
• Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia. 2000;41(s1):35–39.
   PubMedGoogle Scholar
• Ghaemi SN. Toward a Hippocratic psychopharmacology. Can J Psychiatry. 2008;53(3):189–196.
   PubMed Web of Science ®Google Scholar
• Gold SM, Irwin MR. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Immunol Allergy Clin. 2009;29(2):309–320.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Kardash L, Novello S, et al. Progress in bipolar disorder drug design toward the development of novel therapeutic targets: a clinician’s perspective. Expert Opin Drug Discov. 2018;13(3):221–228.
   PubMed Web of Science ®Google Scholar
• Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–370.
   PubMed Web of Science ®Google Scholar
• Beck AT, Steer RA, Brown GK. BDI-fastscreen for medical patients: manual: psychological corporation. New York, NY: Psychological Press; 1987.
   Google Scholar
• Fornaro M, Grunebaum MF, Burke AK, et al. Comparison of familial and non-familial suicidal behaviors among people with major depressive disorder: testing the discriminative predicting role of high-yield clinical variables. J Psychiatr Res. 2018 Jul;102:118–122. doi: 10.1016/j.jpsychires.2018.02.021. Epub 2018 Feb 23.
   PubMed Web of Science ®Google Scholar
• Fornaro M, De Berardis D, Mazza M, et al. Factor structure and reliability of the Italian adaptation of the hypomania check list-32, second revision (HCL-32-R2). Journal of Affective Disorders. 2015;178:112–120.
   PubMed Web of Science ®Google Scholar
• de Cerqueira AC, de Andrade PS, Barreiros JMG, et al. Psychiatric disorders in patients with multiple sclerosis. Compr Psychiatry. 2015;63:10–14.
   PubMed Web of Science ®Google Scholar
• Cerqueira A, Nardi AE, Souza-Lima F, et al. Bipolar disorder and multiple sclerosis: comorbidity and risk factors. Revista Brasileira de Psiquiatria. 2010;32(4):454–456.
   PubMed Web of Science ®Google Scholar
• Carta MG, Angst J. Epidemiological and clinical aspects of bipolar disorders: controversies or a common need to redefine the aims and methodological aspects of surveys. Clin Pract Epidemiol Ment Health. 2005;1(1):4.
   PubMedGoogle Scholar
• Fornaro M, Elassy M, Mounir M, et al. Factor structure and reliability of the Arabic adaptation of the Hypomania Check List-32, second revision (HCL-32-R2). Compr Psychiatry. 2015;59:141–150.
   PubMed Web of Science ®Google Scholar
• Higuera L, Carlin CS, Anderson S. Adherence to disease-modifying therapies for multiple sclerosis. Journal Managed Care Specialty Pharmacy. 2016;22(12):1394–1401.
   PubMed Web of Science ®Google Scholar
• Feinstein A. Multiple sclerosis, disease modifying treatments and depression: a critical methodological review. Multiple Sclerosis Journal. 2000;6(5):343–348.
   PubMedGoogle Scholar
• Chuang D-M. Neuroprotective and neurotrophic actions of the mood stabilizer lithium: can it be used to treat neurodegenerative diseases? Crit Reviews™ Neurobiol. 2004;16:1&2.
   PubMedGoogle Scholar
• Ungerleider JT, Andyrsiak T, Fairbanks L, et al. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Advances in Alcohol & Substance Abuse. 1988;7(1):39–50.
   Google Scholar
• Iskedjian M, Bereza B, Gordon A, et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007;23(1):17–24.
   PubMed Web of Science ®Google Scholar
• Zohar J, Nutt DJ, Kupfer DJ, et al. A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol. 2014;24(7):1005–1014.
   PubMed Web of Science ®Google Scholar
• Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Investigative Med 2017. jim–2016–0003397.
   PubMedGoogle Scholar
• Schröder A, Klotz P, Lee D-H, et al. Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: A pilot analysis. Clin Neurol Neurosurg. 2011;113(7):527–530.
   PubMed Web of Science ®Google Scholar
• Nocentini U, Caltagirone C, Tedeschi G. Neuropsychiatric dysfunction in multiple sclerosis. Milan, Italy: Springer; 2012. DOI:10.1007/978-88-470-1711-5
   Google Scholar